Poland· PL-100362289
Humira
A adalimumab product containing adalimumabum, registered in Poland by AbbVie Deutschland GmbH & Co. KG. The same ATC class is registered in 14 of our 19 countries.
Checked against URPL (Poland) on
Informational only — not a medical device.
Where it is registered
Adalimumab is registered in 14 of 19 countries.
Countries holding a registration under ATC L04AB04 (adalimumab), each read from that country’s own register.
- This record: Poland, from URPL (Poland)
- 9 of them publish a price we can compare per daily dose
Adalimumab · ATC L04AB04
14 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Icelandprice
- Ireland
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of adalimumab costs, country by country.
Normalised to the WHO defined daily dose (2.9 mg), the median price runs from $0.015 in France to $36.00 in Switzerland — a ×2384 gap.
- 2 markets with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Adalimumab · price per daily dose (2.9 mg)
USD · FX 28 Sept 2026
- CH Switzerland$36.00
- FR France$0.015
The record
At a glance
URPL (Poland)- Active substance
- Adalimumabum
- Manufacturer
- AbbVie Deutschland GmbH & Co. KG
- Country
- Poland (PL)
- ATC code
- L04AB04
- ATC class
- Adalimumab
- Defined daily dose
- 2.9 mg, P
- Reimbursed
- Not published by this register
- Source register
- URPL (Poland)
- Last checked
- September 27, 2026
Packs & prices · 2
- gtin08054083011905
- gtin08054083011912
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
429 interactions on record for adalimumab.
Graded by severity as the source publishes them — 286 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Adalimumab · interactions on record
429 records
- 286 severe
- 136 moderate
- 7 minor
Most severe, free to view
- PrednisoloneA07EA01severe
- HydrocortisoneA07EA02severe
- PrednisoneA07EA03severe
- BetamethasoneA07EA04severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Adalimumab in 15 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- SwitzerlandAmgevita
- SwedenAMGEVITA 20 mg/0,2 ml Injektionsvätska, lösning i förfylld sprutaAmgen Europe B.V.
- CzechiaAMGEVITAAmgen Europe B.V., Breda
- FinlandAMGEVITAAmgen Europe B.V.
- United StatesAdalimumabSandoz Inc
- BelgiumAmgevita 20 mgAmgen Europe
- IcelandAmgevitaAmgen Europe B.V.*
- NetherlandsAmgevita 20 mg, oplossing voor injectie in een voorgevulde spuitAmgen Europe B.V.
Authorised across Europe · EMA
The same active substance is authorised in 4 EEA countries. Names it is sold under:
- United Kingdom (Northern Ireland) · Hukyndra, Humira
- Iceland · Amgevita, Amsparity
- Liechtenstein · Amsparity, Hefiya
- Norway · Amgevita, Amsparity
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/71874b01-fb1d-4424-8627-e8e8981e092a GET /v1/drugs/71874b01-fb1d-4424-8627-e8e8981e092a?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Roztwór do wstrzykiwań",
"source": "urpl",
"strength": "40 mg/0,4 ml",
"packaging": "Rpz ¦ EU/1/03/256/012 ¦ 113706\n1 amp.-strzyk. 0,4 ml + 1 gazik nasączony z alkoholem\n08054083011905 ¦ Rpz ¦ EU/1/03/256/013 ¦ 113707\n2 amp.-strzyk. 0,4 ml + 2 gaziki nasączone z alkoholem\nRpz ¦ EU/1/03/256/014 ¦ 113708\n4 amp.-strzyk. 0,4 ml + 4 gaziki nasączone z alkoholem\nRpz ¦ EU/1/03/256/015 ¦ 113709\n6 amp.-strzyk. 0,4 ml + 6 gazików nasączonych z alkoholem\n08054083011912 ¦ Rpz ¦ EU/1/03/256/017 ¦ 113753\n2 wstrzykiwacze 0,4 ml + 2 gaziki\nRpz ¦ EU/1/03/256/018 ¦ 119841\n4 wstrzykiwacze 0,4 ml + 4 gaziki\nRpz ¦ EU/1/03/256/019 ¦ 119842\n6 wstrzykiwaczy 0,4 ml + 6 gazików\nRpz ¦ EU/1/03/256/016 ¦ 119843\n1 wstrzykiwacz 0,4 ml + 2 gaziki",
"substance": "Adalimumabum 40 mg/0,4ml",
"common_name": "Adalimumabum",
"pl_product_id": "100362289",
"pozwolenie_nr": null,
"auth_procedure": "CEN",
"authorisation_validity": null
}See everything about adalimumab.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.